Get started
Award

U10 CA046441

Funded outputs count: 110
Funder award ID: U10 CA046441
OpenAlex ID: G1985252453
Race-Dependent Differences in Risk, Genomics, and Epstein–Barr Virus Exposure in Monoclonal Gammopathies: Results of SWOG S0120
2020 · Madhav V. Dhodapkar, Rachael Sexton, et al. · Clinical Cancer Research · 8
PDF
Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421
2017 · Guru Sonpavde, Gregory R. Pond, et al. · Clinical Genitourinary Cancer · 6
Disease Control Rate at 8 Weeks Predicts Subsequent Survival in Platinum-Treated Extensive Stage Small-Cell Lung Cancer: Results From the Southwest Oncology Group (SWOG) Database
2015 · Primo N. Lara, James Moon, et al. · Clinical Lung Cancer · 13
PDF
Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial
2015 · Ranjana H. Advani, Fangxin Hong, et al. · Journal of Clinical Oncology · 36
PDF
SWOG S0722: Phase II Study of mTOR Inhibitor Everolimus (RAD001) in Advanced Malignant Pleural Mesothelioma (MPM)
2015 · Sai-Hong Ignatius Ou, James Moon, et al. · Journal of Thoracic Oncology · 80
A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Combination of Bevacizumab (NSC-704865) in Patients With Inoperable Locally Advanced Stage III Non–Small-Cell Lung Cancer: SWOG S0533
2015 · Antoinette J. Wozniak, James Moon, et al. · Clinical Lung Cancer · 49
PDF
Relevance of Platinum-Sensitivity Status in Relapsed/Refractory Extensive-Stage Small-Cell Lung Cancer in the Modern Era: A Patient-Level Analysis of Southwest Oncology Group Trials
2014 · Primo N. Lara, James Moon, et al. · Journal of Thoracic Oncology · 27
SWOG S0221: A Phase III Trial Comparing Chemotherapy Schedules in High-Risk Early-Stage Breast Cancer
2014 · George T. Budd, William E. Barlow, et al. · Journal of Clinical Oncology · 120
PDF
Endocrine Therapy With or Without Inhibition of Epidermal Growth Factor Receptor and Human Epidermal Growth Factor Receptor 2: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Fulvestrant With or Without Lapatinib for Postmenopausal Women With Hormone Receptor–Positive Advanced Breast Cancer—CALGB 40302 (Alliance)
2014 · Harold J. Burstein, Constance T. Cirrincione, et al. · Journal of Clinical Oncology · 86
PDF
Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: A phase III metastatic castration resistant prostate cancer trial
2014 · Amir Goldkorn, Benjamin Ely, et al. · International Journal of Cancer · 44
PDF
Dual blockade of epidermal growth factor receptor and insulin‐like growth factor receptor–1 signaling in metastatic pancreatic cancer: Phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG S0727)
2014 · Philip A. Philip, Bryan Goldman, et al. · Cancer · 94
PDF
Southwest Oncology Group S0802: A Randomized, Phase II Trial of Weekly Topotecan With and Without Ziv-Aflibercept in Patients With Platinum-Treated Small-Cell Lung Cancer
2014 · Jeffrey W. Allen, James Moon, et al. · Journal of Clinical Oncology · 76
PDF
Adjuvant Vaccine Immunotherapy of Resected, Clinically Node-Negative Melanoma: Long-term Outcome and Impact of HLA Class I Antigen Expression on Overall Survival
2014 · William E. Carson, Joseph M. Unger, et al. · Cancer Immunology Research · 15
Circulating Tumor Cells and Response to Chemotherapy in Metastatic Breast Cancer: SWOG S0500
2014 · Jeffrey B. Smerage, William E. Barlow, et al. · Journal of Clinical Oncology · 648
PDF
Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904
2014 · Robert L. Coleman, James Moon, et al. · European Journal of Cancer · 30
Circulating Tumor Cell Counts Are Prognostic of Overall Survival in SWOG S0421: A Phase III Trial of Docetaxel With or Without Atrasentan for Metastatic Castration-Resistant Prostate Cancer
2014 · Amir Goldkorn, Benjamin Ely, et al. · Journal of Clinical Oncology · 321
S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma
2014 · A B El-Khoueiry, C Rankin, et al. · British Journal of Cancer · 121
PDF
A phase II study of docetaxel and vinorelbine plus filgrastim for HER-2 negative, stage IV breast cancer: SWOG S0102
2013 · Julie R. Gralow, William E. Barlow, et al. · Breast Cancer Research and Treatment · 2
PDF
Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432
2013 · Harry P. Erba, Megan Othus, et al. · Leukemia Research · 22
Phase II Trial of Carboplatin, Paclitaxel, Cetuximab, and Bevacizumab Followed by Cetuximab and Bevacizumab in Advanced Nonsquamous Non–Small-Cell Lung Cancer: SWOG S0536
2013 · Edward S. Kim, James Moon, et al. · Journal of Thoracic Oncology · 32
PDF
Autologous Transplantation as Consolidation for Aggressive Non-Hodgkin's Lymphoma
2013 · Patrick J. Stiff, Joseph M. Unger, et al. · New England Journal of Medicine · 343
PDF
Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120)
2013 · Madhav V. Dhodapkar, Rachael Sexton, et al. · Blood · 192
A Comparative Analysis of Prognostic Factor Models for Follicular Lymphoma Based on a Phase III Trial of CHOP–Rituximab versus CHOP + 131Iodine—Tositumomab
2013 · Oliver W. Press, Joseph M. Unger, et al. · Clinical Cancer Research · 41
A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia
2013 · Sucha Nand, Megan Othus, et al. · Blood · 71
Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528
2013 · Shirish M. Gadgeel, Danika L. Lew, et al. · Cancer Chemotherapy and Pharmacology · 25
Year
Topic